

-11-

**REMARKS**

Claims 1-6, 8, 10, 15-20, 22-23 and 25-35 are pending in the application. Claims 1 and 16 are currently amended. Claims 21 and 28 are currently cancelled. Claims 2-6, 8, 10, 15-23 and 25-35 were previously presented, and claims 7, 9, 11-14 and 24 were previously canceled.

The Examiner requested clarification on the status of claims 21 and 28. Applicants intend to cancel these claims and have listed these claims as cancelled herein.

No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry. In view of the amendments made herein and the remarks below, applicants respectfully request reconsideration and withdrawal of the rejection set forth in the June 23, 2005 Office Action.

**Rejection under 35 USC § 112, Second Paragraph**

The Examiner rejected claim 1 and its dependant claims 2-4, 6-18, 20-22, 24-51 and 54-59 under 35 USC § 112, second paragraph, as allegedly being indefinite based on the definition of W.

Without prejudice and solely in the interests of facilitating prosecution, applicants have amended claim 1 to clarify the definition of W and how a spiro ring may be formed from it.

Accordingly, in view of the amendment made herein and the remarks above, applicants respectfully submit that claims 1-4, 6-18, 20-22, 24-51 and 54-59 are patentable under 35 USC § 112, second paragraph, and therefore request that the Examiner withdraw the rejection.

The Examiner rejected claim 58 as being indefinite, allegedly because "formula I" was recited in the claim, but was not provided and because of an improper Markush group.

Without prejudice and solely in the interests of facilitating prosecution, applicants have amended claim 58 to refer to formula I according to claim 1, as well as to have the Markush recitation in the alternate form and in singular.

In view of the amendments set forth herein and remarks above, applicants respectfully submit that the pending claims are fully allowable, and solicit the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

-12-

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: August 2, 2005



Jason G. Tebbutt  
Attorney for Applicant(s)  
Reg. No. 55,671

Jolene Appleman  
Attorney for Applicant(s)  
Reg. No. 35,428

Pfizer Inc  
Patent Department  
150 East 42nd Street – 5<sup>th</sup> Floor  
New York, NY 10017-5755  
(212) 733-4827